DIN/NPN/PIN 02413175 SIMPONI 100 MG / SYR INJECTION SYRINGE GOLIMUMAB |
|
|||||
Date Listed/Coverage Update: | 18-Dec-2018 | ||||
Unit Price: | 1,516.0000 | ||||
LCA Price: | N/A | ||||
MAC Price: |
N/A |
||||
Unit of Issue: | Syringe | ||||
Manufacturer: | JANSSEN INC. (JAI) | ||||
ATC: | L04AB06 | ||||
1 | |||||
Interchangeable Products: | No | ||||
Coverage Status: | SPECIAL AUTHORIZATION |
Applies to Clients of: | Non-Group Coverage (Group 1) Coverage for Seniors (Group 66) Palliative Coverage (Group 20514, Please note your client may have Group 1 or Group 66 coverage) Child and Family Services (Group 20403) Alberta Child Health Benefit (Group 20400) Children and Youth Services (Group 19824) Income Support (Group 19823) Alberta Human Services (AISH) (Group 19823) Alberta Adult Health Benefit (AAHB) (Group 23609) |
Special Authorization Request Form: | |
Expand all |
|
Special authorization coverage may be provided for the reduction in signs and symptoms and induction and maintenance of clinical remission of Ulcerative Colitis in adult patients (18 years of age or older) with active disease (characterized by a partial Mayo score >4 prior to initiation of biologic therapy) and who are refractory or intolerant to: - mesalamine: minimum of 4 grams/day for a minimum of 4 weeks; AND - corticosteroids (failure to respond to prednisone 40 mg daily for 2 weeks, or; steroid dependent i.e. failure to taper off steroids without recurrence of disease or disease requiring a second dose of steroids within 12 months of previous dose). 'Refractory' is defined as lack of effect at the recommended doses and for duration of treatments specified above. 'Intolerant' is defined as demonstrating serious adverse effects or contraindications to treatments as defined in product monographs. Immunosuppressive therapy as follows may also be initiated if in the clinician's judgment a trial is warranted: i) Azathioprine: minimum of 2 mg/kg/day for a minimum of 2 months; OR ii) 6-mercaptopurine: minimum of 1 mg/kg/day for a minimum of 2 months For coverage, this drug must be prescribed by a Specialist in Gastroenterology as recognized by the College of Physicians and Surgeons and/or the Alberta Medical Association or a physician appropriately trained by the University of Alberta or the University of Calgary and recognized as a prescriber by Alberta Blue Cross ('Specialist'). Initial coverage may be approved for 200 mg of golimumab administered by subcutaneous injection at Week 0, followed by 100 mg at Week 2. As an interim measure, an additional dose of 50 mg of golimumab will be provided at weeks 6 and 10 to allow time to determine whether the patient meets coverage criteria for maintenance dosing, see below. - Patients will be limited to receiving a one-month supply of golimumab per prescription at their pharmacy. - Patients will be permitted to switch from one biologic agent to another following an adequate trial of the first biologic agent if unresponsive to therapy, or due to serious adverse effects or contraindications. An adequate trial is defined as at a minimum the completion of induction dosing (e.g. initial coverage period). - Patients will not be permitted to switch back to a previously trialed biologic agent if they were deemed unresponsive to therapy. - Patients are limited to receiving one biologic agent at a time regardless of the condition for which it is being prescribed. For continued coverage beyond three doses, the patient must meet the following criteria: 1) The patient must be assessed by a Specialist between week 12 and week 14 to determine response. 2) The Specialist must confirm in writing that the patient is a 'responder' that meets the following criteria: - a decrease in the partial Mayo score of greater than or equal to 2 points Following this assessment, continued coverage may be approved for a dose of 50 mg every 4 weeks for a period of 12 months. Ongoing coverage may be considered only if the following criteria are met at the end of each 12-month period: 1) The patient has been assessed by a Specialist to determine response; 2) The Specialist must confirm in writing that the patient has maintained a response to therapy as indicated by: - a decrease in the partial Mayo score of greater than or equal to 2 points from the score prior to initiation of golimumab therapy Note: For patients who showed a response to induction therapy then experienced secondary loss of response while on maintenance dosing with 50 mg, the maintenance dose may be adjusted from 50 mg to 100 mg by making an additional special authorization request to Alberta Blue Cross for the increased dose. All requests (including renewal requests) for golimumab for Ulcerative Colitis must be completed using the Adalimumab/Golimumab/Infliximab/Ozanimod/Tofacitinib/Vedolizumab for Ulcerative Colitis Special Authorization Request Form (ABC 60008). |
Review Status / Past Decisions
|